Bausch Health Cos Inc. (NYSE:BHC) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Bausch Health Cos Inc. (NYSE:BHC) have received a consensus rating of “Hold” from the seven brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $8.00.

Several research firms have recently commented on BHC. Jefferies Financial Group upgraded shares of Bausch Health Cos to a “hold” rating in a research note on Wednesday, July 22nd. Zacks Research upgraded shares of Bausch Health Cos from a “hold” rating to a “strong-buy” rating in a research note on Monday. Weiss Ratings raised shares of Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, July 31st. Finally, Wall Street Zen upgraded shares of Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st.

Insider Transactions at Bausch Health Cos

In other Bausch Health Cos news, insider Aimee Lenar sold 36,827 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $7.03, for a total transaction of $258,893.81. Following the transaction, the insider owned 334,853 shares in the company, valued at approximately $2,354,016.59. The trade was a 9.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 20.67% of the company’s stock.

Institutional Trading of Bausch Health Cos

Hedge funds have recently modified their holdings of the business. Paulson & CO. Inc. acquired a new stake in shares of Bausch Health Cos in the second quarter valued at about $361,151,000. Dimensional Fund Advisors LP grew its position in Bausch Health Cos by 10.8% during the first quarter. Dimensional Fund Advisors LP now owns 3,604,818 shares of the company’s stock worth $19,456,000 after buying an additional 350,823 shares during the period. MFN Partners Management LP acquired a new position in Bausch Health Cos during the second quarter worth about $29,580,000. Royal Bank of Canada increased its holdings in Bausch Health Cos by 24.9% in the first quarter. Royal Bank of Canada now owns 11,363,498 shares of the company’s stock valued at $61,362,000 after buying an additional 2,262,894 shares in the last quarter. Finally, Hillsdale Investment Management Inc. purchased a new position in Bausch Health Cos in the fourth quarter valued at about $3,651,000. 78.65% of the stock is owned by institutional investors and hedge funds.

Bausch Health Cos Price Performance

Bausch Health Cos stock opened at $5.64 on Friday. Bausch Health Cos has a 12 month low of $4.33 and a 12 month high of $8.00. The company has a debt-to-equity ratio of 54.68, a current ratio of 1.44 and a quick ratio of 1.08. The business has a 50 day simple moving average of $5.99 and a 200-day simple moving average of $5.51. The stock has a market capitalization of $2.11 billion, a PE ratio of -1.91 and a beta of 0.37.

Bausch Health Cos (NYSE:BHC) last issued its quarterly earnings results on Wednesday, July 29th. The company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.30. The firm had revenue of $2.83 billion during the quarter, compared to the consensus estimate of $2.59 billion. Bausch Health Cos had a negative return on equity of 561.95% and a negative net margin of 10.12%. Equities analysts predict that Bausch Health Cos will post 4.35 earnings per share for the current year.

Bausch Health Cos Company Profile

Bausch Health Companies Inc is a multinational specialty pharmaceutical company headquartered in Laval, Quebec. The company develops, manufactures and markets prescription medicines, over-the-counter products and medical devices, with a focus on gastroenterology, neurology, dermatology and other specialty therapeutic areas.

Its portfolio includes gastrointestinal treatments such as Xifaxan, Trulance and Relistor, as well as products for conditions affecting the central nervous system and skin.